Data investigation
CJC-1295 and Ipamorelin: What FDA Recorded
Sold as a stack for fat loss. FDA identified serious adverse events with CJC-1295 (increased heart rate and systemic vasodilatory reaction), and neither peptide has a weight-loss trial.
CJC-1295 and ipamorelin are sold together, usually as a “stack”, on the theory that one extends a growth hormone pulse while the other triggers it. Both are flagged in FDA’s compounding safety records, and one of them carries language stronger than FDA used for most other peptides in this market: “serious adverse events… including increased heart rate and systemic vasodilatory reaction.”[1]
Neither is approved for anything, and neither has been tested for weight loss. The human trial data that exist measured hormone levels or treated an entirely unrelated condition.
Where each one actually sits
| CJC-1295 | Ipamorelin acetate | |
|---|---|---|
| FDA listing | Nominated for the 503A list, then withdrawn | Active category 2 under 503B, added September 29, 2023, and separately withdrawn from its 503A nomination |
| Immunogenicity | Flagged for certain routes of administration | Flagged, from potential aggregation or peptide-related impurities |
| Characterization | Complexities with impurities and identifying the active ingredient | Contains unnatural amino acids, adding complexity to characterization |
| Adverse events | Serious events named in the entry: a raised heart rate, and a systemic vasodilatory reaction | Serious adverse events, including death, from a published study of intravenous use for gastric motility |
| Clinical data | “Available clinical data are limited.” | — |
“FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”[1]— FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
FDA’s 2024 briefing says CJC-1295’s developer withdrew the DAC form from clinical trials in 2006 after a phase 2 participant died.[7] FDA calls its sources for the details anecdotal. They describe a person with HIV lipodystrophy who had chest discomfort about two hours after an 11th weekly dose, an ECG-confirmed heart attack, and death about an hour later. The attending physician’s leading explanation was undiagnosed coronary artery disease, so this does not show the drug caused the death. The trial’s data were never published.[7]
The theory behind stacking them
The two act on different receptors, which is the whole argument for combining them. CJC-1295 is a growth hormone-releasing hormone analog engineered for a long half-life. Ipamorelin is a ghrelin mimetic, described in the literature as the first selective growth hormone secretagogue, meaning it raises GH without the cortisol and prolactin rises that made earlier compounds in its class unattractive.[2] That selectivity was shown in pigs; how it compares with the older hexarelin, whose cortisol rise was measured in people, is set out separately.
That pharmacology is real. CJC-1295 does produce prolonged elevation of growth hormone and IGF-I in humans, which is what the 2006 trial measured.[3] The gap is what comes next: raising a hormone is not the same as producing a clinical result, and the second step has not been tested.
What the human trials actually studied
- CJC-1295, 2006. Prolonged stimulation of GH and IGF-I secretion in humans. An endocrine measurement study, not a weight or body-composition trial.[3]
- Ipamorelin, 1998. The original characterization paper establishing it as a selective GH secretagogue.[2]
- Ipamorelin, 1999. Pharmacokinetic and pharmacodynamic modeling in human volunteers.[4]
- Ipamorelin, 2014. A randomized, controlled proof-of-concept study for the management of postoperative ileus, a bowel-motility problem after surgery.[5] Nothing to do with weight.
Against what the sellers list beside it
On the same menu you will typically find compounded semaglutide or tirzepatide. Those molecules have phase 3 trials with thousands of participants and body weight as the primary endpoint. This pair has hormone-level studies and an ileus trial.
The pairing is easy to find in our register. Dr. Gillis’ Wellness Center, Live Vital and DrBrainRx list CJC-1295 with ipamorelin beside semaglutide and tirzepatide, and so do RxPepsDirect, ElitePhysiqMD and Iron Med RX. Thriving Again and TeleCareSpot list ipamorelin on its own next to their GLP-1 programs. Iron Med RX and TeleCareSpot do not name the pharmacy that fills their orders, which makes the second question below harder to answer before you buy.
None of this says growth hormone does nothing. It demonstrably affects body composition in people who are deficient in it. The question is what has been demonstrated in people who are not. The same gap runs through sermorelin, which does have an approval history and has no weight-loss trial either. How the two peptides in the stack differ from each other is in CJC-1295 vs ipamorelin, and CJC-1295 on its own, including FDA’s 2024 advisory vote on it, has its own CJC-1295 profile. The public catalog at System Labs lists sermorelin as an injection or a tablet, and neither CJC-1295 nor ipamorelin.
If you are being offered the stack
- Ask about the cardiovascular effects by name. FDA identified increased heart rate and systemic vasodilatory reaction with CJC-1295. A seller offering it should be able to discuss that rather than hear it from you.
- Ask which pharmacy compounds it and under what authority, given that ipamorelin is in active category 2 for 503B and CJC-1295 is on neither list. Neither is among the six peptides in HHS’s interim enforcement-discretion policy of October 28, 2026, and that policy covers single-ingredient products only, so a combined stack falls outside it in any case.[6]
- Ask for the weight-loss trial. Not a mechanism and not a case series, but the trial itself. Notice what arrives instead.
- Ask what it adds to the GLP-1 you are already paying for, and what that addition costs per month.
Common questions
Frequently Asked Questions
References
- 1.U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — entries for CJC-1295 and Ipamorelin acetate FDA Human Drug Compounding. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- 2.Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue Eur J Endocrinol. 1998. PMID: 9849822.
- 3.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults J Clin Endocrinol Metab. 2006. PMID: 16352683.
- 4.Gobburu JV, Agersø H, Jusko WJ Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers Pharm Res. 1999. PMID: 10496658.
- 5.Beck DE, Sweeney WB, McCarter MD Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus Int J Colorectal Dis. 2014. PMID: 25331030.
- 6.U.S. Department of Health and Human Services HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (with Appendices A and B), announced October 28, 2026 HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- 7.U.S. Food and Drug Administration FDA Briefing Document for CJC-1295 Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, December 4, 2024 FDA. 2024. https://www.fda.gov/media/183819/download
Compare the sellers
Related research
BPC-157 FDA Status: What the Agency Put on the Record
Not approved, and not on the list of substances a 503A compounding pharmacy may use. FDA recorded specific concerns: immunogenicity, peptide impurities, and “no, or only limited, safety-related information”.
8 min read
Tesamorelin for Weight Loss? Read Its Own Label
Tesamorelin is FDA-approved, for reducing abdominal fat in HIV-associated lipodystrophy. Its label carries six words that matter: “Not indicated for weight loss management.”
6 min read
What Cannot Legally Be Compounded, and Who Is Selling It Anyway
Federal law bars retatrutide and cagrilintide from compounding entirely. We checked our own 560-seller register against that rule, found 7 with it on the menu, and discovered our own reviews were not telling readers.
8 min read
What Makes a Telehealth GLP-1 Prescription Legitimate
The FDA publishes seven warning signs for telehealth medicine sellers. Here they are, with what proper prescribing looks like and the one disclosure that 139 of our 560 sellers failed in an August 2026 count.
7 min read
Is the Vial You Received What the Label Says?
FDA has found labels naming compounding pharmacies that do not exist, and labels naming real pharmacies that did not make the product. What to check when the box arrives, and what the 990 adverse event reports mean.
8 min read
What the FDA's GLP-1 Warning Letters Say About This Market
Two letters in 2023, ten in 2024, 72 in 2025. The most common subject is unlawful sale to consumers: enforcement here is overwhelmingly about what sellers said, not what pharmacies made.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →